Distinct pharmacodynamics of insulin glargine and insulin detemir: crossover comparison in Type 1 and Type 2 diabetic patients on basal-bolus regimen

Tomoko Kato; Ichiro Tokubuchi; Kazuhisa Muraishi; Shuichi Sato; Tamotsu Kato; Kento Hara; Kayo Tanaka; Hiroo Kaku; Yuji Tajiri; Kentaro Yamada

doi:10.1016/j.diabres.2010.08.011

Distinct pharmacodynamics of insulin glargine and insulin detemir: crossover comparison in Type 1 and Type 2 diabetic patients on basal-bolus regimen

Diabetes Res Clin Pract. 2010 Dec;90(3):e64-6. doi: 10.1016/j.diabres.2010.08.011. Epub 2010 Sep 17.

Authors

Tomoko Kato¹, Ichiro Tokubuchi, Kazuhisa Muraishi, Shuichi Sato, Tamotsu Kato, Kento Hara, Kayo Tanaka, Hiroo Kaku, Yuji Tajiri, Kentaro Yamada

Affiliation

¹ Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka 830-0011 Japan. yamada@med.kurume-u.ac.jp

PMID: 20850885
DOI: 10.1016/j.diabres.2010.08.011

Abstract

We compared blood glucose profile when glargine or detemir was injected once daily before dinner in combination with pre-meal insulin lispro by a crossover design. Glargine showed lower post-dinner and bedtime glucose levels in Type 1 diabetes, and lower pre-dinner and post-dinner glucose levels in Type 2 diabetes than detemir.

MeSH terms

Adult
Aged
Blood Glucose
Cross-Over Studies
Diabetes Mellitus, Type 1 / drug therapy*
Diabetes Mellitus, Type 2 / drug therapy*
Female
Glycated Hemoglobin
Humans
Hypoglycemic Agents / administration & dosage
Hypoglycemic Agents / therapeutic use
Insulin / administration & dosage
Insulin / analogs & derivatives*
Insulin Detemir
Insulin Glargine
Insulin Lispro
Insulin, Long-Acting
Male
Middle Aged
Postprandial Period

Substances

Blood Glucose
Glycated Hemoglobin A
Hypoglycemic Agents
Insulin
Insulin Lispro
Insulin, Long-Acting
Insulin Glargine
Insulin Detemir